Breaking News Instant updates and real-time market news.

RAD

Rite Aid

$0.81

-0.0374 (-4.40%)

, MLHR

Herman Miller

$30.23

-0.46 (-1.50%)

18:57
12/19/18
12/19
18:57
12/19/18
18:57

Fly Intel: After Hours Movers

UP AFTER EARNINGS: Rite Aid (RAD) up 8.5%... Herman Miller (MLHR) up 7.9%. ALSO HIGHER: Tilray (TLRY) up 14.6% after forming THC/ CBD beverage partnership with AB InBev... Safe Bulkers (SB) up 8.9% after announcing 3M share stock buyback... Newell (NWL) up 5.3% after increased stake by Carl Icahn... Celanese (CE) up 4.4% after announced entry into S&P 500 index... Latam Airlines (LTM) up 2.4% after FY19 margin, capacity guidance. DOWN AFTER EARNINGS: Pier 1 Imports (PIR) down 15.3%... REV Group (REVG) down 11.1%... Limoneira (LMNR) down 5.1% after FY18, initial FY19 guidance. ALSO LOWER: DBV Technologies (DBVT) down 48.8% after pulling FDA Viaskin Peanut application, competitor Aimmune (AIMT) up 10.8% on the announcement... Spectrum Pharma (SPPI) down 34.9% after FDA declined breakthrough status for poziotinib... G1 Therapeutics (GTHX) down 24.4% after announcing topline data from trilaciclib study relative to placebo... MannKind Corp (MNKD) down 18.3% after equity offering.

RAD

Rite Aid

$0.81

-0.0374 (-4.40%)

MLHR

Herman Miller

$30.23

-0.46 (-1.50%)

TLRY

Tilray

$71.00

-5.77 (-7.52%)

SB

Safe Bulkers

$1.69

-0.08 (-4.52%)

NWL

Newell Brands

$20.42

-0.99 (-4.62%)

CE

Celanese

$84.86

-0.53 (-0.62%)

LTM

Latam Airlines

$9.93

-0.09 (-0.90%)

PIR

Pier 1 Imports

$1.13

0.12 (11.88%)

REVG

REV Group

$9.00

-0.5 (-5.26%)

LMNR

Limoneira

$19.98

0.13 (0.65%)

DBVT

DBV Technologies

$14.12

-0.58 (-3.95%)

AIMT

Aimmune

$21.74

-0.15 (-0.69%)

SPPI

Spectrum

$10.40

-0.21 (-1.98%)

GTHX

G1 Therapeutics

$28.68

0.18 (0.63%)

MNKD

MannKind

$1.70

0.03 (1.80%)

  • 19

    Dec

  • 19

    Dec

  • 19

    Dec

  • 20

    Dec

  • 20

    Dec

  • 30

    Jan

  • 31

    Jan

  • 20

    Dec

RAD Rite Aid
$0.81

-0.0374 (-4.40%)

10/12/18
RHCO
10/12/18
NO CHANGE
Target $75
RHCO
Hold
Walgreens Boots Alliance price target raised to $75 from $66 at SunTrust
SunTrust analyst David MacDonald raised his price target on Walgreens Boots Alliance (WBA) to $75 after its Q4 earnings beat and FY19 guidance yesterday. The analyst says the results were marked by "solid U.S. pharmacy performance" in spite of the ongoing reimbursement and generic headwinds. MacDonald also keeps his Hold rating, adding that while the company's cash flow remains "robust" and the integration of Rite Aid (RAD) is still on track, he is concerned about the challenging environment and ongoing degradation in gross margins.
11/19/18
JEFF
11/19/18
NO CHANGE
JEFF
Jefferies uncovers signs of Amazon expanding prescription drug presence
Jefferies analyst Brian Tanquilut says his proprietary checks of Amazon.com's (AMZN) moves in the pharmacy space indicate that the online retailer has finally made moves to expand PillPack. However, the initial expansion phase appears focused on offering pharmacy services to Amazon employees in Washington. In his most recent webscrape, Tanquilut came across a new prescription license in WA, two pending Rx licenses in New Mexico and Indiana, and pharmacy technician and packaging/shipping job postings all linked to PillPack's Phoenix facility. These new developments signal the beginning of Amazon's prescription expansion via PillPack, Tanquilut tells investors in a research note. If Amazon were to rollout a more extensive PillPack offering to its own employee base, Rite Aid (RAD) could be most exposed to potential script transfers with Walgreens Boots Alliance (WBA) the least exposed among the public drugstores, says the analyst. He still believes that the impact of Amazon's pharmacy entry will take a while to materialize for drug stores CVS Health (CVS) and Walgreens.
09/28/18
LOOP
09/28/18
NO CHANGE
Target $1.35
LOOP
Hold
Rite Aid price target lowered to $1.35 at Loop Capital on Albertsons deal
Loop Capital analyst Andrew Wolf lowered his price target on Rite Aid to $1.35 from $1.75 and kept his Hold rating after its Q2 results, saying that while the Pharmacy Services segment showed improved sales profitability, this was offset by lower profitability in Retail Pharmacy. The analyst added that the discount on the Rite Aid stock relative to the broader pharmacy group is "appropriate" given its "high debt leverage and subscale operations". Wolf further notes that the board's caving to shareholder pressure to cancel the Albertsons deal was a mistake directly linked to the 28% decline in the stock price since August 8th.
12/14/18
GSCO
12/14/18
DOWNGRADE
Target $68
GSCO
Sell
Goldman downgrades Walgreens to Sell with $68 target, sees downside in 2019
Goldman Sachs analyst Robert Jones downgraded Walgreens Boots Alliance (WBA) to Sell from Neutral and lowered his price target for the shares to $68 from $73. The analyst says he struggles to make a "compelling fundamental case" for the Americas Healthcare Services Supply Chain heading into 2019 as "issues facing core growth drivers do not seem to be abating." Jones sees limited "core" growth for the large-cap names amid persisting sales and margin pressures and as drug pricing remains a regulatory focus. He downgrades Walgreens to Sell saying challenges in its retail pharmacy business "have intensified, forcing the company to search for other avenues of growth." Jones also keeps a Neutral rating on CVS Health (CVS) and Sell rating on Rite Aid (RAD).
MLHR Herman Miller
$30.23

-0.46 (-1.50%)

12/26/17
RAJA
12/26/17
UPGRADE
Target $43
RAJA
Outperform
Herman Miller upgraded to Outperform from Market Perform at Raymond James
Raymond James analyst Budd Bugatch upgraded Herman Miller to Outperform and established a $43 price target following newly passed tax reform. The analyst believes the economic backdrop favors a strong office furniture demand environment and tax reform increases incentives for office furniture purchases given immediate expensing of short-term capital assets.
12/26/17
12/26/17
NO CHANGE

On The Fly: Top five analyst actions
Catch up on today's top five analyst rating changes with this list compiled by The Fly: 1. Raymond James analyst Budd Bugatch upgraded Herman Miller (MLHR) to Outperform following newly passed tax reform, as the analyst believes the economic backdrop favors a strong office furniture demand environment and tax reform increases incentives for office furniture purchases. 2. Bugatch also upgraded Knoll (KNL) following the enactment of U.S. tax reform, as he believes its sales force, new product offerings, competitive pricing, and recently announced Muuto acquisition position the company to drive revenue growth as macro conditions improve. 3. Janney Capital analyst Michael Gaugler upgraded Unitil (UTL) to Buy citing the stock's "compelling" valuation. 4. William Blair analyst Tim Lugo late Friday downgraded Agile Therapeutics (AGRX) to Market Perform from Outperform after the company received a complete response letter from the FDA over its hormonal contraceptive patch, Twirla. While the issues raised by the FDA may be addressable, he has concerns regarding management's execution of the company's lead product. 5. Ignyta (RXDX) was downgraded to Hold at SunTrust and to Neutral at Ladenburg after the company agreed to be acquired by Roche (RHHBY) for $27 per share. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
TLRY Tilray
$71.00

-5.77 (-7.52%)

11/14/18
BNCH
11/14/18
NO CHANGE
Target $200
BNCH
Buy
Tilray reported 'strong' Q3 sales without recreational cannabis, says Benchmark
Benchmark analyst Mike Hickey said Tilray reported "strong" Q3 sales even though the company did not recognize sales from recreational cannabis use in the quarter. Recreational use experienced a slow start, primarily due to the timing of licenses, distribution and retail infrastructure, as expected, said Hickey, who adds that there "appears to be exceedingly strong demand" from Canadians. He has raised his Q4 sales forecast based on increased production and presumed ongoing strong consumer demand and keeps a Buy rating on Tilray with a $200 price target.
11/06/18
COWN
11/06/18
NO CHANGE
COWN
Demand for adult use cannabis 'seemingly strong' in Canada, says Cowen
Citing her analysis of e-commerce platforms for adult use cannabis in Canada, Cowen analyst Vivien Azer remains encouraged to see "seemingly strong demand" as well as some instances of improved supply. In a research note pre-market open, the analyst notes she aggregated 533 product offerings with 1,149 SKUs from the e-commerce platforms for Alberta, British Columbia, Ontario, New Brunswick, and Newfoundland and Labrador. Overall, SKU stockout rates across the provinces were flat versus last week at 57%, although remains above the 46% rate during the prior week, Azer adds. Her view of the data is a modest positive for Canopy Growth (CGC), which has the second highest number of SKUs and out of stock rates declined from 65% to 54% while adding 16 SKUs this week. The read-through on Tilray (TLRY) is less clear, Azer contends, as the only three provinces where the company did not get supply agreements were all in her five province survey universe. The analyst reiterated an Outperform rating on Canopy Growth and Tilray.
11/07/18
ADAM
11/07/18
NO CHANGE
ADAM
Midterms broadly positive for U.S. cannabis industry, says Canaccord
Canaccord analyst Bobby Burleson says that as expected, yesterday's midterms delivered several wins for the U.S. cannabis industry, including the passage of three state ballot measures on legalization, key gubernatorial victories by pro-cannabis candidates, and the retaking of the House by Democrats. The analyst views these results as broadly positive for the U.S. cannabis industry. Publicly traded companies in the space include Aurora Cannabis (ACB), CV Sciences (CVSI), CannTrust Holdings (CNTTF), Canopy Growth (CGC), Cronos Group (CRON), General Cannabis (CANN), India Globalization Capital (IGC) and Tilray (TLRY).
12/18/18
COWN
12/18/18
NO CHANGE
COWN
Outperform
Cowen sees Sandoz deal as reinforcing Tilray's competitive positioning
Tilray's (TLRY) expanded global partnership with Novartis (NVS) division Sandoz can not only help expand its reach with pharmacists, physicians and distributors, it can also help Tilray capture early share in new medical cannabis markets as they come online, Cowen analyst Vivien Azer tells investors in a research note. Further, the analyst believes the partnership also helps legitimize cannabis in international markets, which could help influence countries considering medical cannabis legalization. Azer estimates international will represent 15% of Tilray's revenue in fiscal 2020 and 22% in fiscal 2021. Not only does the deal allow Tilray to expand geographic reach, but also to grow at scale, says Azer. And most notably, the Sandoz deal reinforces Tilray's competitive positioning, adds the analyst, who keeps an Outperform rating on the shares with a $150 price target. The stock in morning trading is up 9%, or $5.98, to $71.87.
SB Safe Bulkers
$1.69

-0.08 (-4.52%)

10/18/18
10/18/18
UPGRADE

Outperform
Safe Bulkers upgraded to Outperform on valuation, earnings at Evercore ISI
As previously reported, Evercore ISI upgraded Safe Bulkers to Outperform from In Line. Analyst Jonathan Chappell said the disconnect between dry bulk equity prices and spot rates continues to widen due to global trade/macro fears. Chappell views Safe Bulkers' valuation as steeply discounted and raised his rating amid a renewed focus on operating earnings leverage and balance sheet flexibility.
10/18/18
10/18/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Nike (NKE) upgraded to Outperform from Perform at Oppenheimer with analyst Brian Nagel saying Nike represents an "already dominant, legacy global brand that is now aggressively embracing the power of digital to enhance most facets of its business." 2. United Continental (UAL) upgraded to Outperform from Neutral at Macquarie and to Overweight from Equal Weight at Stephens. 3. Generac (GNRC) upgraded to Neutral from Sell at Goldman Sachs with analyst Jerry Revich saying the company's organic growth outlook is improving amid rising power disturbances. 4. Proteostasis (PTI) upgraded to Outperform from Sector Perform at RBC Capital with analyst Brian Abrahams citing an "impressive" set of data from its phase 2 cystic fibrosis doublet trial. 5. Safe Bulkers (SB) upgraded to Outperform from In Line at Evercore ISI with analyst Jonathan Chappell saying the disconnect between dry bulk equity prices and spot rates continues to widen due to global trade/macro fears. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/09/18
JEFF
11/09/18
UPGRADE
Target $3.5
JEFF
Buy
Safe Bulkers upgraded to Buy from Hold at Jefferies
Jefferies analyst Randy Giveans upgraded Safe Bulkers to Buy with a $3.50 price target.
11/09/18
JEFF
11/09/18
UPGRADE
Target $3.5
JEFF
Buy
Jefferies calls Safe Bulkers undervalued, upgrades shares to Buy
Jefferies analyst Randy Giveans upgraded Safe Bulkers to Buy from Hold with an unchanged price target of $3.50. The stock has traded down recently with capesize rates amid Australian iron ore supply disruptions, but Capesizes make up only four of Safe Bulkers' 41-vessel fleet, Giveans tells investors in a research note. The analyst points out that smaller asset class spot rates, time charter rates, and asset values "remain firm." He thinks the shares, currently trading at a 20% discount to estimated net asset value, are undervalued. Safe Bulkers shares should perform well as rates improve in the coming weeks/months, says Giveans.
NWL Newell Brands
$20.42

-0.99 (-4.62%)

09/20/18
WELS
09/20/18
NO CHANGE
Target $33
WELS
Outperform
Wells sees 'significant' upside in Newell, even in bear case scenario
Wells Fargo analyst Bonnie Herzog continues to see value in Newell Brands that she thinks the Street is missing. The analyst believes Newell's $10B divestiture plan will "unlock significant value" and leave a "simpler, faster growing" company with "significant" exposure to e-commerce "that should ultimately garner a higher multiple." Additional divestiture announcements and a better fundamental outlook for the second half of 2018 provide near-term catalysts for the shares, Herzog tells investors in a research note titled "We See Significant Upside Potential Even In Bear Case Scenario." The analyst sees limited downside risk to current share levels and believes the new board is highly focused on unlocking value. She thinks that if the shares remain weak, the board would not hesitate to explore more aggressive actions like a management change or complete break-up. Herzog sees a favorable risk/reward, with potential 17% upside in a bear case and 75% upside in a bull case. She reiterates an Outperform rating on Newell Brands with a $33 price target.
09/24/18
WELS
09/24/18
NO CHANGE
WELS
Outperform
Newell weakness on potential Sears bankruptcy fears overdone, says Wells Fargo
Wells Fargo analyst Bonnie Herzog believes today's weakness in shares of Newell Brands (NWL) is likely due to concerns about a potential bankruptcy of Sears (SHLD) as well as ongoing China tariff negotiations. However, she views the move as a "complete overreaction," arguing that Newell's exposure to Sears is fairly limited. Herzog, who sees today's weakness as overblown and would be a buyer amid the weakness, reiterates her Outperform rating on Newell shares, which are down 7% to $20.28 in late morning trading.
11/05/18
BMOC
11/05/18
NO CHANGE
Target $20
BMOC
Market Perform
Newell Brands price target lowered to $20 from $25 at BMO Capital
BMO Capital analyst Shannon Coyne lowered the price target on Newell Brands to $20, saying its Q3 earnings of 81c included a tax benefit. The analyst notes that while the company may have turned the corner with accelerating sales and operating margin improvement, it is also faced with "persistent headwinds in appliances/baby/home fragrance/Coleman" categories along with rising input cost and tariff risks. Coyne keeps Newell Brands rating at Market Perform.
11/05/18
JEFF
11/05/18
NO CHANGE
Target $20
JEFF
Hold
Newell Brands price target lowered to $20 from $23 at Jefferies
Jefferies analyst Kevin Grundy lowered his price target for Newell Brands to $20 following the company's "mixed" Q3 results. While below Street estimates, Newell's Q3 core sales improved sequentially and "cleared the low bar," Grundy tells investors in a research note. Further, he believes the return to growth in Writing is encouraging. However, results missed expectations in the remainder of Newell's portfolio and "myriad risks remain," including tariffs, says Grundy. The analyst remains on the sidelines with a Hold rating.
CE Celanese
$84.86

-0.53 (-0.62%)

12/10/18
STFL
12/10/18
INITIATION
Target $100
STFL
Hold
Celanese initiated with a Hold at Stifel
Stifel analyst Vincent Anderson initiated Celanese with a Hold rating and a price target of $100. The analyst notes that the company's earning's outlook is "solid", but also sees its valuation case as "difficult to make". Anderson adds that Celanese "acetyl business is likely on the wrong side of mid-cycle" and also expects its compounding portfolio to be tested by input inflation.
10/17/18
VERT
10/17/18
UPGRADE
VERT
Buy
Celanese upgraded to Buy from Hold at Vertical Research
Vertical Research upgraded Celanese to Buy from Hold saying shares are oversold given the rebound in the Acetyls Chain.
06/18/18
JEFF
06/18/18
NO CHANGE
Target $138
JEFF
Buy
Celanese price target raised to $138 from $130 at Jefferies
Jefferies analyst Laurence Alexander raised his price target for Celanese to $138 and keeps a Buy rating on the shares. The analyst forecasts 18% annual earnings growth through 2021 and believes demand "remains healthy."
06/15/18
BMOC
06/15/18
NO CHANGE
Target $150
BMOC
Outperform
Celanese price target raised to $150 from $137 at BMO Capital
BMO Capital analyst John McNulty raised his price target on Celanese to $150 and kept his Outperform rating, saying the company's Acetic Acid prices continue their upward trajectory amid a tight supply/demand environment, while the capacity curbs by China also support the pricing dynamic. The analyst notes that risk-reward is solidly to the upside for the stock as prices have now risen 10-14% sequentially in Q2.
LTM Latam Airlines
$9.93

-0.09 (-0.90%)

12/19/18
12/19/18
NO CHANGE

Latam Airlines sees FY19 ASK growth 4%-6%
Sees FY19 ATK growth 1%-3%.
11/26/18
SBSH
11/26/18
UPGRADE
Target $11
SBSH
Neutral
Latam Airlines upgraded to Neutral from Sell at Citi
Citi analyst Stephen Trent upgraded Latam Airlines to Neutral and raised his price target for the shares to $11 from $8. The analyst believes the company is serious about limiting capacity growth given its $2.3B capital expenditure cut. Further, he points out the stock is down 40% since February 6.
07/16/18
GSCO
07/16/18
INITIATION
Target $12
GSCO
Neutral
Latam Airlines initiated with a Neutral at Goldman Sachs
Goldman Sachs started Latam Airlines with a Neutral rating and $12 price target.
03/19/18
JPMS
03/19/18
DOWNGRADE
Target $16.5
JPMS
Underweight
Latam Airlines downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Fernando Abdalla downgraded Latam Airlines to Underweight while raising his price target for the shares to $16.50 from $15.50. The analyst believes the company's margin recovery is reflected in the shares and calls Latam his least favorite airline on relative basis.
PIR Pier 1 Imports
$1.13

0.12 (11.88%)

11/12/18
ARGS
11/12/18
DOWNGRADE
ARGS
Sell
Pier 1 Imports downgraded to Sell from Hold at Argus
06/28/18
LOOP
06/28/18
NO CHANGE
Target $2
LOOP
Hold
Pier 1 Imports' back-half weighted guidance 'concerning,' says Loop Capital
Loop Capital analyst Chukumba lowered his price target on Pier 1 Imports to $2 from $3 and maintained a Hold rating after the company reported Q1 results, telling investors in a research note that there was nothing in the company's performance during the quarter that gave him any indication it is going to "turn the corner" any time soon. Additionally, the analyst says he is "concerned" that the company's FY18 guidance is more back-half weighted than he originally expected, and that the company's plans to introduce more modern merchandise gives him "bad memories" of the last time it tried a similar strategy.
09/20/18
LOOP
09/20/18
NO CHANGE
Target $1.5
LOOP
Hold
Pier 1 Imports price target lowered to $1.50 at Loop Capital after soft Q2
Loop Capital analyst Anthony Chukumba lowered his price target on Pier 1 Imports to $1.50 from $2.00 and kept his Hold rating after its worse-than-expected preliminary Q2 results and withdrawn FY18 guidance. The analyst says this latest update affirms his belief that a turnaround will be more difficult to execute this time around because of a "much more competitive environment", growing e-commerce sales, and having a lot less costs that the company can reduce.
10/03/18
LOOP
10/03/18
NO CHANGE
Target $1.5
LOOP
Hold
Pier 1 Imports gross margin decline much worse than expected, says Loop Capital
Loop Capital analyst Anthony Chukumba kept his Hold rating and $1.50 price target on Pier 1 Imports in an initial takeaway note after its Q2 earnings. The analyst says the company's gross margin was "much worse than expected and indicates the company had to resort to dramatic markdowns to clear unproductive inventory".
REVG REV Group
$9.00

-0.5 (-5.26%)

10/01/18
STFL
10/01/18
DOWNGRADE
STFL
Hold
REV Group downgraded to Hold from Buy at Stifel
09/05/18
DBAB
09/05/18
INITIATION
Target $16
DBAB
Hold
REV Group resumed with a Hold at Deutsche Bank
Deutsche Bank analyst Chad Dillard resumed coverage of REV Group with a Hold rating and $16 price target.
12/19/18
12/19/18
NO CHANGE

REV Group reports Q4 adjusted EBITDA $39.4M vs. $58.4M last year
10/01/18
STFL
10/01/18
DOWNGRADE
Target $17
STFL
Hold
REV Group downgraded to Hold from Buy at Stifel
Stifel analyst Michael Baudendistel downgraded REV Group to Hold from Buy to better reflect near-term headwinds that are likely to persist for a couple or few quarters in many cases, in addition to the recent appreciation in its stock price, now about $3 off its low. REV Group has been a "disappointing" stock this year, the analyst tells investors in a research note, and says he is moving to the sidelines for now. Baudendistel cut his price target slightly to $17 from $18, or 7.5x his 2019 EBITDA estimate of $190M.
LMNR Limoneira
$19.98

0.13 (0.65%)

09/11/18
LSCM
09/11/18
NO CHANGE
Target $31
LSCM
Buy
Limoneira shares will likely sell off today, says Lake Street
Lake Street analyst Chris Krueger expects shares of Limoneira to sell off today following last night's earnings shortfall on weather. The stock had risen 65% since February and was pricing in expectations of a Q3 beat and guidance increase, neither of which happened, Krueger tells investors in a post-earnings research note. While sales beat estimates, poor weather hurt margins and caused an earnings miss, the analyst explains. However, he remains confident Limoneira will continue to grow its core agribusiness and generate additional cash flow from its real estate and water rights. Krueger raised his price target for the shares to $31 from $30 and keeps Buy rating on the name.
06/28/18
STFL
06/28/18
INITIATION
Target $30
STFL
Buy
Limoneira initiated with a Buy at Stifel
Stifel analyst Vincent Anderson initiated Limoneira with a Buy and $30 price target. Anderson believes the company is well positioned to generate strong growth from its existing pipeline of of newly planted acres and expanded pack house, and when combined with reduced capital spending, will generate strong free cash flows. Limoneira is also pursuing an aggressive acquisition strategy, focused on increasing its footprint abroad, which should add significant value beyond current estimates, Anderson wrote in a note to investors.
09/11/18
BUCK
09/11/18
NO CHANGE
Target $32
BUCK
Buy
Limoneira positioned for another year of growth, says Buckingham
Buckingham analyst Eric Larson raised his price target for Limoneira to $32 from $30, while reiterating a Buy rating on the shares. The analyst believes Limoneira is still positioned for another year of growth in FY18 behind a new efficient lemon packing plant, increased lemon volumes, additional lemon acreage, and a solid return to profitability in oranges. Further, additional runway for growth in FY19 is now being supported by two accretive acquisitions, he adds.
06/28/18
06/28/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. CBS (CBS) initiated with an Outperform at Imperial Capital. 2. Limoneira (LMNR) initiated with a Buy at Stifel. 3. Keryx (KERX) initiated with a Buy at H.C. Wainwright. 4. Zosano Pharma (ZSAN) initiated with a Buy at BTIG. 5. Gilead (GILD) initiated with a Strong Buy at Raymond James. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
DBVT DBV Technologies
$14.12

-0.58 (-3.95%)

12/19/18
PIPR
12/19/18
NO CHANGE
PIPR
Overweight
Aimmune retains competitive edge over DBV Technologies, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond thinks the recent disclosure that DBV Technologies' (DBVT) Viaskin Peanut may be excluded from the PDUFA program would likely mean an extended FDA review time, which he said "bodes well" for competitor Aimmune (AIMT), which this morning announced the initiation of its Phase 3 POSEIDON trial assessing the efficacy of AR101 in peanut-allergic children. Given that he reads the trial start as a sign that the FDA remains comfortable with the safety profile of AR101, and his view on AR101's clinical profile, Raymond said he believes Aimmune "retains the competitive edge" over DBV. He keeps an Overweight rating on Aimmune shares.
09/13/18
STFL
09/13/18
INITIATION
Target $35
STFL
Buy
DBV Technologies initiated with a Buy at Stifel
Stifel analyst Derek Archila initiated DBV Technologies with a Buy rating and a price target of $35, saying the stock offers a "favorable" risk-reward over the next 12 months. Archila acknowledges investors' skepticism due to the Viaskin peanut missing its Phase 3 lower confidence level, but adds that his talks with regulatory experts suggest an over 50% probability that the Viaskin Biologic License Application will be accepted and yield an eventual approval.
04/18/18
04/18/18
NO CHANGE
Target $37

Buy
Pediatric allergist sees both DBV, Aimmune winning approval, says Jefferies
Jefferies analyst Eun Yang hosted a discussion panel with a pediatric allergist who believes both both DBV Technologies' (DBVT) Viaskin Peanut and Aimmune's (AIMT) AR101 will be approved by the FDA. The allergist thinks Viaskin would be preferable due to its lower burden of monitoring and AR101 would be preferred due to its stronger efficacy, Yang tells investors in a research note. The doctor believes choice of treatment, if both are approved, will depend on a patients' goal of treatment and preference. Yang has a Buy rating on DBV Technologies with a $37 price target.
08/20/18
JMPS
08/20/18
NO CHANGE
Target $30
JMPS
Outperform
DBV Viaskin Peanut BLA acceptance could be derisking event, says JMP Securities
After hosting meetings with Kevin Trapp, DBV Technologies' newly appointed Chief Commercial Officer, JMP Securities analyst Liisa Bayko noted the company is prepared to submit its BLA for Viaskin Peanut in October and she looks for acceptance 60 days later, which she said would be the first positive milestone for the company and could be a "meaningful derisking event." Viaskin Peanut is eligible for priority review and her expectation is that DBV will receive it, added Bayko, who reiterated her Outperform rating and $30 price target on the shares.
AIMT Aimmune
$21.74

-0.15 (-0.69%)

12/13/18
GSCO
12/13/18
INITIATION
Target $32
GSCO
Neutral
Aimmune initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Paul Choi initiated coverage of Aimmune Therapeutics with a Neutral rating and $32 price target. The analyst thinks the company's peanut allergy treatment AR101 is more than likely to be approved, but he expects a "relatively slow launch."
12/13/18
PIPR
12/13/18
NO CHANGE
Target $60
PIPR
Overweight
Piper remains buyer of Aimmune into 'catalyst-rich' 2019
Piper Jaffray analyst Christopher Raymond says "strong support" from allergists at Aimmune Therapeutics' "positive" investor day. The analyst continues to like the stock setup and says he remains a buyer of the stock into a "catalyst-rich" 2019. Raymond keeps an Overweight rating on Aimmune with a $60 price target.
12/13/18
CANT
12/13/18
NO CHANGE
Target $64
CANT
Overweight
Aimmune current range an attractive entry point, says Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan sees the current Aimmune Therapeutics trading range as an attractive entry point. He reiterates an Overweight rating on the shares with a $64 price target after attending the company's analyst day.
SPPI Spectrum
$10.40

-0.21 (-1.98%)

09/06/18
JEFF
09/06/18
NO CHANGE
Target $25
JEFF
Buy
Spectrum should begin to retrace last week's selloff, says Jefferies
Jefferies analyst Matthew Andrews says the new interim poziotinib data from the MD Anderson Phase 2 non-small cell lung cancer study "don't disappoint." Shares of Spectrum Pharmaceuticals should begin to retrace the drop since last week amid concerns about the Korean poziotinib HER2 data, Andrews tells investors in a research note. The analyst believes the unconfirmed overall response rate of 58% in EGFR and 50% in HER2 are "impressive." He keeps a Buy rating on Spectrum with a $25 price target.
11/12/18
RILY
11/12/18
NO CHANGE
Target $29
RILY
Buy
Spectrum price target lowered to $29 from $35 at B. Riley FBR
B. Riley FBR analyst David Buck lowered his price target for Spectrum Pharmaceuticals to $29 to reflect "some more conservatism" given the recent weakness in the group and passing of some expected catalysts. Poziotinib remains the key pipeline focus, with the company filing for breakthrough therapy confirmed with its Q3 results, Buck tells investors in a research note. He keeps a Buy rating on Spectrum.
08/31/18
RILY
08/31/18
NO CHANGE
Target $35
RILY
Buy
Spectrum price target raised to $35 from $26 at B. Riley FBR
B. Riley FBR analyst David Buck raised his price target for Spectrum Pharmaceuticals to $36 and keeps a Buy rating on the shares ahead of the company's September 5 data abstract.
09/06/18
HCWC
09/06/18
NO CHANGE
Target $40
HCWC
Buy
Spectrum price target raised to $40 from $34 at H.C. Wainwright
H.C. Wainwright analyst Edward White raised his price target for Spectrum Pharmaceuticals to $40 after the company presented at his firm's conference. The analyst remains optimistic about both the stock and the company's pipeline, which he notes includes poziotinib in non-small cell lung cancer and HER2-positive breast cancer and Rolontis in chemotherapy-induced neutropenia. Progress is being made across developmental programs along with upcoming catalysts, White tells investors in a research note. He keeps a Buy rating on Spectrum.
GTHX G1 Therapeutics
$28.68

0.18 (0.63%)

09/10/18
BTIG
09/10/18
INITIATION
Target $80
BTIG
Buy
G1 Therapeutics assumed with a Buy at BTIG
BTIG analyst Thomas Shrader assumed G1 Therapeutics with a Buy rating and a price target of $80, citing the company's "unique" position of potentially developing two "best in class" CDK4/6 inhibitors - trilaciclib and lerociclib. The analyst notes that trilaciclib's positive outcomes support its efficacy and looks ahead to the 2nd line SCLC data later this year. Shrader adds that while the stock is no longer cheap, having risen nearly 400% since its IPO, "significant upside" in the stock price remains thanks to the "large market opportunity" of both programs that he estimates to be around $2B by 2025.
09/17/18
HCWC
09/17/18
NO CHANGE
Target $79
HCWC
Buy
G1 Therapeutics price target raised to $79 from $61 at H.C. Wainwright
H.C. Wainwright analyst Edward White raised his price target for G1 Therapeutics to $79 saying the company, in his opinion, makes positive revision to its Phase 2 protocol in newly diagnosed small cell lung cancer patients. The analyst views the earlier availability of comprehensive myelopreservation data as a positive that could add substantially to discussions with regulators in early 2019. Following the announcement of the revised protocol, White has increased confidence in the approval of trilaciclib. He keeps a Buy rating on G1 Therapeutics.
09/18/18
NEED
09/18/18
NO CHANGE
Target $76
NEED
Buy
G1 Therapeutics price target raised to $76 from $60 at Needham
Needham analyst Chad Messer raised his price target on G1 Therapeutics to $76 and kept his Buy rating, citing the company's announcement yesterday of amended phase 2 trial protocol for trilaciclib testing in combination with chemotherapy and Tecentrq. The analyst believes that the myelopreservation data from this trial "may help bolster the available dataset" that the company is planning to bring to the FDA in the first half of 2019 for discussion regarding a viable path to approval. Messer adds that he looks forward to the "updated data from the randomized frontline SCLC trial of trilaciclib at ESMO in October".
12/19/18
RAJA
12/19/18
INITIATION
Target $66
RAJA
Strong Buy
G1 Therapeutics initiated with a Strong Buy at Raymond James
Raymond James initiated G1 Therapeutics with a Strong Buy and a $66 price target.
MNKD MannKind
$1.70

0.03 (1.80%)

06/07/18
HCWC
06/07/18
NO CHANGE
Target $5
HCWC
Buy
MannKind's treprostinil could be 'transformational asset,' says H.C. Wainwright
MannKind's (MNKD) announcement this morning of a successful Phase 1 completion of its Technosphere treprostinil dry powder inhalation for pulmonary arterial hypertension comes months ahead of schedule, H.C. Wainwright analyst Oren Livnat tells investors in a research note. The news is an important reminder that MannKind's inhalation drug delivery platforms offer potentially much more value than just Afrezza inhalable insulin, the analyst contends. He believes inhalable treprostinil, which is not yet in his model, could "ultimately prove a transformational asset." Livnat points out that United Therapeutics' (UTHR) pulmonary arterial hypertension treprostinil franchise is estimated to deliver over $1.1B of sales in 2018. The analyst keeps a Buy rating on MannKind with a $5 price target.
06/26/18
HCWC
06/26/18
NO CHANGE
Target $5
HCWC
Buy
MannKind gained 'new credibility' for Afrezza at ADA, says H.C. Wainwright
H.C. Wainwright analyst Oren Livnat said MannKind materially increased Afrezza's relevance and gained "new credibility" with multiple data presentations, including a well-attended symposium and oral presentation, at the American Diabetes Association meeting that was just held. He called the event an "eye-opening experience" that showed Afrezza's defining differentiation is not that it is inhalable, but that it "really is the best meal-time insulin, full stop." Following the ADA event, Livnat reiterated his Buy rating and $5 target on MannKind shares.
08/03/18
HCWC
08/03/18
NO CHANGE
Target $4
HCWC
Buy
MannKind price target lowered to $4 from $5 at H.C. Wainwright
H.C. Wainwright analyst Oren Livnat lowered his price target for MannKind to $4 citing the company's "light" Q2 results. The analyst, however, still models for an Afrezza ramp in the second half of the year. He remains remain "very bullish long-term if the product can be resourced" and keeps a Buy rating on MannKind.
09/05/18
HCWC
09/05/18
NO CHANGE
Target $4
HCWC
Buy
MannKind valuation 'floor' raised with United deal, says H.C. Wainwright
H.C. Wainwright analyst Oren Livnat says United Therapeutics (UTHR) is the "ideal partner" for MannKind (MNKD) to develop and commercialize technosphere treprostinil dry powder inhalation for pulmonary arterial hypertension. The deal announced yesterday represents additional validation of MannKind's "underappreciated" DPI and delivery platforms beyond Afrezza, Livnat tells investors in a research note. Importantly, the deal brings in non-dilutive financing, "raises the floor" on MannKind's valuation, and "offers a new path to potential long-term upside from here even if Afrezza never reaches the potential we think it deserves," Livnat writes. The analyst reiterates a Buy rating on MannKind shares with a $4 price target. The stock closed yesterday up 89%, or 98c, to $2.08.

TODAY'S FREE FLY STORIES

SPHHF

Sophos Group

$0.00

(0.00%)

19:18
10/14/19
10/14
19:18
10/14/19
19:18
Downgrade
Sophos Group rating change  »

Sophos Group downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RETA

Reata Pharmaceuticals

$100.37

4.57 (4.77%)

, GLUU

Glu Mobile

$5.50

0.025 (0.46%)

18:44
10/14/19
10/14
18:44
10/14/19
18:44
Hot Stocks
Fly Intel: After Hours Movers »

HIGHER: Reata Pharma…

RETA

Reata Pharmaceuticals

$100.37

4.57 (4.77%)

GLUU

Glu Mobile

$5.50

0.025 (0.46%)

SENS

Senseonics

$0.83

-0.025 (-2.92%)

AKRX

Akorn

$3.81

-0.105 (-2.69%)

SFIX

Stitch Fix

$21.21

-0.62 (-2.84%)

ASB

Associated Banc-Corp

$19.92

0.12 (0.61%)

EHTH

eHealth

$53.12

-2.86 (-5.11%)

BLMN

Bloomin' Brands

$18.15

-0.83 (-4.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 24

    Oct

  • 24

    Oct

  • 31

    Oct

  • 06

    Nov

  • 13

    Nov

CPA

Copa Holdings

$99.31

-0.045 (-0.05%)

17:58
10/14/19
10/14
17:58
10/14/19
17:58
Hot Stocks
Copa Holdings reports September capacity down 5.5%, traffic down 0.7% »

Copa Holdings released…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

SPY

SPDR S&P 500 ETF Trust

$296.06

-0.2 (-0.07%)

, SPX

S&P 500

$0.00

(0.00%)

17:35
10/14/19
10/14
17:35
10/14/19
17:35
Periodicals
Path to Brexit deal seen with potential Irish border solution, Telegraph says »

After a positive day of…

SPY

SPDR S&P 500 ETF Trust

$296.06

-0.2 (-0.07%)

SPX

S&P 500

$0.00

(0.00%)

EWU

iShares MSCI United Kingdom ETF

$31.37

-0.27 (-0.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEDG

SolarEdge

$89.14

0.19 (0.21%)

, ISCA

International Speedway

$45.21

0.165 (0.37%)

17:22
10/14/19
10/14
17:22
10/14/19
17:22
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

SolarEdge Technologies…

SEDG

SolarEdge

$89.14

0.19 (0.21%)

ISCA

International Speedway

$45.21

0.165 (0.37%)

GLUU

Glu Mobile

$5.50

0.025 (0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 06

    Nov

  • 13

    Nov

  • 03

    Dec

GLUU

Glu Mobile

$5.50

0.025 (0.46%)

, SEDG

SolarEdge

$89.14

0.19 (0.21%)

17:18
10/14/19
10/14
17:18
10/14/19
17:18
Hot Stocks
Breaking Hot Stocks news story on Glu Mobile, SolarEdge »

Glu Mobile to replace…

GLUU

Glu Mobile

$5.50

0.025 (0.46%)

SEDG

SolarEdge

$89.14

0.19 (0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

  • 13

    Nov

  • 03

    Dec

SEDG

SolarEdge

$89.14

0.19 (0.21%)

, ISCA

International Speedway

$45.21

0.165 (0.37%)

17:17
10/14/19
10/14
17:17
10/14/19
17:17
Hot Stocks
SolarEdge to replace International Speedway in S&P 400 at open on 10/18 »

Nascar Holdings is…

SEDG

SolarEdge

$89.14

0.19 (0.21%)

ISCA

International Speedway

$45.21

0.165 (0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 03

    Dec

SFIX

Stitch Fix

$21.21

-0.62 (-2.84%)

17:12
10/14/19
10/14
17:12
10/14/19
17:12
Initiation
Stitch Fix initiated at Baird »

Stitch Fix initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

BLMN

Bloomin' Brands

$18.15

-0.83 (-4.37%)

17:12
10/14/19
10/14
17:12
10/14/19
17:12
Downgrade
Bloomin' Brands rating change at Deutsche Bank »

Bloomin' Brands…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QIWI

Qiwi

$20.34

0.09 (0.44%)

17:02
10/14/19
10/14
17:02
10/14/19
17:02
Hot Stocks
Qiwi CFO Vladislav Poshmorga resigned effective October 8th »

QIWI plc announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RLMD

Relmada Therapeutics

$11.10

0.4 (3.74%)

16:51
10/14/19
10/14
16:51
10/14/19
16:51
Hot Stocks
Relmada Therapeutics to announces Phase 2 study results of REL-107 on October 15 »

Relmada Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGFS

AgroFresh Solutions

$2.39

0.125 (5.53%)

16:47
10/14/19
10/14
16:47
10/14/19
16:47
Hot Stocks
AgroFresh awarded $31M in damages in Decco Poast-Harvest lawsuit »

AgroFresh was awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EHTH

eHealth

$53.12

-2.86 (-5.11%)

16:47
10/14/19
10/14
16:47
10/14/19
16:47
Initiation
eHealth initiated at Raymond James »

eHealth initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

GPN

Global Payments

$164.14

1.2 (0.74%)

16:38
10/14/19
10/14
16:38
10/14/19
16:38
Initiation
Global Payments initiated  »

Global Payments initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 31

    Oct

  • 13

    Nov

APTS

Preferred Apartment

$14.41

0.075 (0.52%)

16:36
10/14/19
10/14
16:36
10/14/19
16:36
Hot Stocks
Preferred Apartment names Joel Murphy as CEO, effective January 1, 2020 »

Preferred Apartment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OHI

Omega Healthcare

$43.05

0.65 (1.53%)

16:36
10/14/19
10/14
16:36
10/14/19
16:36
Hot Stocks
Omega Healthcare raises quarterly dividend to 67c from 66c per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

RPAY

Repay Holdings

$13.21

-0.07 (-0.53%)

16:35
10/14/19
10/14
16:35
10/14/19
16:35
Hot Stocks
Breaking Hot Stocks news story on Repay Holdings »

Repay Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 19

    Nov

SQ

Square

$61.83

0.29 (0.47%)

16:34
10/14/19
10/14
16:34
10/14/19
16:34
Initiation
Square initiated  »

Square initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 29

    Oct

  • 06

    Nov

FISV

Fiserv

$106.05

0.41 (0.39%)

, FDC

First Data

$0.00

(0.00%)

16:34
10/14/19
10/14
16:34
10/14/19
16:34
Initiation
Fiserv, First Data initiated at UBS »

Fiserv initiated with a…

FISV

Fiserv

$106.05

0.41 (0.39%)

FDC

First Data

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Oct

  • 27

    Oct

LDOS

Leidos

$82.50

-0.66 (-0.79%)

16:31
10/14/19
10/14
16:31
10/14/19
16:31
Hot Stocks
Leidos awarded $926M TSA screening equipment contract »

Leidos was awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 12

    Nov

RETA

Reata Pharmaceuticals

$100.37

4.57 (4.77%)

16:30
10/14/19
10/14
16:30
10/14/19
16:30
Hot Stocks
Breaking Hot Stocks news story on Reata Pharmaceuticals »

Reata Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
10/14/19
10/14
16:30
10/14/19
16:30
Options
Preliminary option volume of 13.7M today »

Preliminary option volume…

FIS

FIS

$132.70

0.69 (0.52%)

16:29
10/14/19
10/14
16:29
10/14/19
16:29
Initiation
FIS initiated at UBS »

FIS initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 19

    Nov

AKRX

Akorn

$3.81

-0.105 (-2.69%)

16:28
10/14/19
10/14
16:28
10/14/19
16:28
Hot Stocks
Akorn gets FDA approval for Betamethasone Dipropionate Lotion, augmented »

Akorn announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

EHTH

eHealth

$53.12

-2.86 (-5.11%)

16:27
10/14/19
10/14
16:27
10/14/19
16:27
Initiation
eHealth initiated at Raymond James »

eHealth initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.